Posts

Collaboration between UC Davis Foods for Health and Company Spin-off Evolve BioSystems Identifies Detrimental Generational Change in Gut Bacteria of Infants

Collaboration between UC Davis Foods for Health and Company Spin-off Evolve BioSystems Identifies Detrimental Generational Change in Gut Bacteria of Infants

Evolve BioSystems, Inc., a spin-off from the UC Davis Foods for Health Institute (FFHI) that is developing novel solutions to restore and maintain a healthy newborn gut microbiome, announced findings from new research that connects elevated infant fecal pH levels to a change in the infant gut microbiome. Their release states that over the past 100 years, the average pH of a baby’s stool, which can indicate the type of bacteria in the baby’s gut, has undergone an alarming increase from pH 5.0 to 6.5. The study, published in the American Society for Microbiology journal mSphere, connects this rise in pH to a generational loss of Bifidobacterium, a critical gut bacteria during infancy, and an accompanying increase in a number of harmful bacteria.

The team reviewed 14 clinical studies published between 1926 and 2017, identifying a change in pH from 5.0 to 6.5 over this time period. The authors attributed this trend to an observed reduction of Bifidobacterium in the infant gut, along with an increase in potentially harmful bacteria such as E. coli and Clostridia, resulting in “dysbiosis”, a potentially detrimental imbalance of the gut microbial ecosystem.

Evolve’s founding team, which includes UC Davis faculty members Bruce German, David Mills, Carlito Lebrilla and Daniela Barile, along with former FFHI Assistant Director Samara Freeman, has been conducting research at the forefront of infant nutritional health for over a decade, focusing on the key role that breast milk plays in creating a healthy intestinal tract.

The full release can be found here.

UC Davis Startup Evolve BioSystems Announces Results of Clinical Study

baby holding mothers finger

Evolve BioSystems, Inc., a spin-off from the UC Davis Foods for Health Institute (FFHI) that is developing novel solutions to restore and maintain a healthy newborn gut microbiome, announced today the outcome of its clinical study evaluating the probiotic product B. infantis EVC001 in breast-fed infants.  In its press release, the company stated that the study showed that providing dietary B. infantis EVC001 resulted in rapid, substantial, and persistent remodeling of the gut microbiome in breastfed infants, leading to a reduction in the amount of potentially harmful bacteria.

Evolve’s founding team, which includes UC Davis faculty members Bruce German, David Mills, Carlito Lebrilla and Daniela Barile, along with former FFHI Assistant Director Samara Freeman, has been conducting research at the forefront of infant nutritional health for over a decade, focusing on the key role that breast milk plays in creating a healthy intestinal tract. The company is led by nutrition and health industry veterans Timothy Brown, the company’s CEO, and David Kyle, the company’s Board Chairman and Chief Scientific Officer.

“These results with B. infantis EVC001 demonstrate for the first time that when the appropriate probiotic bacteria are provided in combination with breast milk, they can rapidly and stably colonize the infant gut microbiome while significantly reducing levels of potentially harmful bacteria linked to long-term disease,” said Mark Underwood M.A.S., M.D., Chief of Pediatric Neonatology and Professor of Pediatrics at the University of California Davis, and a principle investigator on the study. “This study is extremely important for infant health and nutrition because we may now have the potential to impact many common health issues by simply restoring the microbiome to its natural state.”

”We are thrilled to see the successful translation of university research into beneficial health outcomes for infants with the potential to persist into later life,” said Dushyant Pathak, associate vice chancellor of Research and executive director of Venture Catalyst at UC Davis. “This success is particularly heartening given the close working relationship developed with the company and support provided by the InnovationAccess and Venture Catalyst teams at UC Davis”

View Evolve’s press release for more information.

UC Davis Spin-off Company, Evolve BioSystems, Secures $20 Million in Funding

UC Davis Spin-off Company, Evolve BioSystems, Secures $20 Million in Funding from Investment Groups to Advance Targeted Microbiome Products

Evolve BioSystems Inc., a spin-off from the UC Davis Foods For Health Institute, that is developing novel solutions to restore and maintain a healthy newborn gut microbiome, announced that it has completed a $20 million Series B financing to fund the commercialization of its initial products.

The company is developing activated probiotic and prebiotic products based on research that shows the infant gut microbiome plays a critical role in the development of a healthy immune system and early metabolic programing as well as meeting the infant’s dietary needs.

Evolve’s founding team, which includes UC Davis faculty members Bruce German, David Mills, Carlito Lebrilla and Daniela Barile, along with previous UC Davis scientist Dr. Samara Freeman, has been conducting research at the forefront of infant nutritional health for over a decade, with a focus on understanding the key role of breast milk in creating a healthy intestinal tract.

The company states the funding will support ongoing clinical activities, operational expansion, and the launch of the initial commercial products. It will also support the development and commercialization of additional animal health products, which aim to restore the balance of nursing animals’ microbiomes.

Read more here.